Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App




New Test Diagnoses C. difficile with One Assay and No Retesting

By LabMedica International staff writers
Posted on 23 Feb 2015
A new CE-IVD certified molecular test provides rapid, accurate, single-test detection of toxigenic Clostridium difficile without the need for confirmatory retesting.

Greiner Bio-One International GmbH (Frickenhause, Germany, and Kremsmünster, Austria) has now added the Genspeed C.diff OneStep assay to its growing portfolio of CE-IVD certified molecular diagnostic tests for nosocomial infections. More...
Genspeed C.diff OneStep identifies toxigenic C. difficile by combining detection of 4 biomarkers: glutamatdehydrogenase (GDH), Toxin A, Toxin B, binary toxin in a single test. Complete analysis takes under 100 min (depending on PCR-cycler used), including detection on the Genspeed R2 Analyzer.

Genspeed C.diff OneStep’s new “1-test – 4-results” procedure avoids the currently used sequential 2-step procedures that combine different test systems and assay principles for GDH and the C. difficile toxins. It also provides conclusive results without the need for confirmatory re-testing and enables inter-laboratory comparisons of results.

Ready-to-use reagents and automated dispensing minimize the number of manual processing steps within the workflow. The Genspeed R2 Analyzer represents a reliable solution that is virtually service-free system, simple to operate, and available at an attractive cost-benefit ratio.

The new test addresses one of the most serious threats worldwide as C. difficile causes one of the most common serious healthcare system associated infections. In a 2013 report, the USA Center for Disease Control (CDC) categorized C. difficile infections as “Threat Level Urgent,” the highest level available.

All Genspeed products are currently available for sale in the EU and EFTA countries only.

Related Links:

Greiner Bio-One 
Genspeed Analyzer and Assays
Genspeed C.diff OneStep, assay brochure


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.